

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
MARIE-CLAUDE GINGRAS, ET AL. : EXAMINER: BELYAVSKYI
SERIAL NO: 10/021,509 :
FILED: DECEMBER 7, 2001 : GROUP ART UNIT: 1644
FOR: TREM-1 SPLICE VARIANT FOR :
USE IN MODIFYING IMMUNE
RESPONSES

INTERVIEW SUMMARY OF THE DISCUSSION OF OCTOBER 14, 2010

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

This interview summary is filed following the examiner initiated interview that occurred on October 14, 2010 with the applicant Eugene Roussel.

SUBSTANCE OF THE INTERVIEW

Propositions were made by the examiner to amend the Claims to bring them in condition of allowance. For Claim 1, the applicant agreed to delete the language “equivalent” but requested that the language “or a portion of amino acid 1-136 of SEQ ID NO: 2” was added after ... a soluble polypeptide, a fragment according to SEQ ID NO: 2,... The examiner agreed to this change based on the fact that it was granted by the Board of Appeal (Decision p.13).

For Claim 3, the applicant agreed to delete the language “equivalent” but disagreed to drop the language “can have several additions, deletions, fusions and/or substitutions of amino acids in any combination”. However, the applicant agreed to consider another style of writing from the examiner. The examiner said he would call back. The examiner called again the same day and proposed the following: “The method of Claim 1, wherein said polypeptide, said fragment duplicate SEQ ID NO: 2”. The applicant agreed if the claim include “or a portion of amino acid 1-136 of SEQ ID NO: 2” at the end of the Claim.

As agreed on October 14, Claim 3 was reading as follow: “ The method of Claim 1, wherein said polypeptide, said fragment duplicate SEQ ID NO: 2, or a portion of amino acid 1-136 of SEQ ID NO: 2. Applicant agreed also to delete the language “equivalent” in Claim 11. Below is presented the complete set of Claims after the amendments agreed on that day.

AMENDMENTS TO THE CLAIMS

Claims 2, 4, 6-10, 12-14 and 17-39 are cancelled. Claims 1, 3, 5, 11, 15, 16, 40, 41, and 42 are active in this application. Claims 1, 3, and 11 are amended as agreed.

1. (Amended) A method of modulating an immune response including administering to an animal, in need thereof, a composition comprising a soluble polypeptide, a fragment according to SEQ ID NO: 2, or a portion of amino acid 1-136 of SEQ ID NO: 2, in an amount effective to modulate the levels of TREM-1 and /or ligand binding activity whereby the immune response is modulated in the animal.

2. (Canceled)

3. (Amended) The method of claim 1, wherein said polypeptide, said fragment duplicate SEQ ID NO: 2, or a portion of amino acid 1-136 of SEQ ID NO: 2.

4. (Canceled)

5. (Previously Presented) The method of claim 1 or 3, wherein said immune response is an inflammatory response.

Claims 6-10. (Canceled)

11. (Amended) The method of claim 1 or 3, wherein said polypeptide, said fragment are admixed with a pharmaceutical carrier.

Claims 12-14 (Cancelled)

15. (Previously Presented) The method of claim 1 or 3, wherein the animal is suffering from a disease or condition is selected from the group consisting of organ transplant/rejection, bone marrow transplant/rejection, graft versus host disease, infectious disease, and an autoimmune disease.

16. (Previously Presented) The method of claim 15, wherein the disease or condition is an infectious disease and which is septic arthritis or septic shock.

17-39. (Canceled)

40. (Previously Presented) The method of claim 15, wherein the disease or condition is an autoimmune disease and which is rheumatoid arthritis, lupus, multiple sclerosis and ulcer.

41. (Previously Presented) The method of claim 1, wherein the composition modulates LPS-induced cytokine production.

42. (Previously Presented) The method of claim 1 or 3, wherein the animal is a human.

Respectfully submitted,



Customer Number

76171

Tel: (713) 988-3003
Fax: (713) 988 -3030

Eugene Roussel Ph.D.
CEO GenePrint Corporation